← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
51	51 Neurogene NGNE $479M	35	-4	-10%	$139M
52	52 Lakefront Biotherapeutics American Depositary Shares LKFT $1.96B	32	-12	-27%	$367M
53	53 ProQR Therapeutics PRQR $205M	29	-3	-9%	$46.9M
54	54 DELISTED BRAINSTORM CELL THERAPUTC BCLI	28	+5	+22%	$4.52M
55	55 CareDx CDNA $3.45B	25	+2	+9%	$24.3M
56	56 Imunon IMNN $5.95M	24	-1	-4%	$3.3M
57	57 DELISTED Carisma Therapeutics CARM	23	-6	-21%	$1.67M
58	58 Wave Life Sciences WVE $629M	23	+4	+21%	$192M
59	HTGM 59 DELISTED HTG Molecular Diagnostics, Inc. Common Stock HTGM	21	+1	+5%	$10M
60	ONCS 60 DELISTED OncoSec Medical Incorporated ONCS	20	-6	-23%	$4.43M
61	61 Capricor Therapeutics CAPR $423M	19	+1	+6%	$1.86M
62	62 Ocugen OCGN $276M	19	+1	+6%	$12.3M
63	63 Mesoblast MESO $1.81B	17	+3	+21%	$32.7M
64	64 DELISTED BioLife Solutions BLFS	16	+3	+23%	$653K
65	PTE 65 DELISTED PolarityTE, Inc. Common Stock PTE	11	-1	-8%	$598K
66	CYAD 66 DELISTED Celyad Oncology SA American Depositary Shares CYAD	8	-2	-20%	$20.8M
67	67 Enlivex Ltd ENLV $4.46M	8	-3	-27%	$5.53M
68	68 ARK Genomic Revolution ETF ARKG $2.09B	6	+3	+100%	$854K
69	69 Eterna Therapeutics ERNA $2.53M	6	0	0%	$2.85M
70	70 Benitec Biopharma BNTC $295M	3	+2	+200%	$743K
71	71 Qiagen QGEN $9.53B	3	+2	+200%	$27.5K
72	72 DELISTED Scorpius Holdings, Inc. SCPX	3	+2	+200%	$1.91M
73	73 Adicet Bio ACET $48.1M	–	–	–	–
74	ACHL 74 DELISTED Achilles Therapeutics ACHL	–	–	–	–
75	75 DELISTED Arcellx ACLX	–	–	–	–